Goldman Sachs’s Longevity Health Holdings XAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-571
Closed -$61.7K – 5892
2023
Q3
$61.7K Sell
571
-13,318
-96% -$2.01M ﹤0.01% 5248
2023
Q2
$4.29M Hold
13,889
– – ﹤0.01% 3236
2023
Q1
$4.23M Sell
13,889
-133
-0.9% -$40.1K ﹤0.01% 3203
2022
Q4
$4.17M Hold
14,022
– – ﹤0.01% 3327
2022
Q3
$4.08M Buy
14,022
+13,269
+1,762% +$3.87M ﹤0.01% 3310
2022
Q2
$219K Hold
753
– – ﹤0.01% 5606
2022
Q1
$220K Hold
753
– – ﹤0.01% 5830
2021
Q4
$218K Buy
753
+330
+78% +$96.2K ﹤0.01% 5854
2021
Q3
$123K Buy
+423
New +$123K ﹤0.01% 5875

Other funds holding XAGE

Goldman Sachs's XAGE Position: Q4 2023 in Review

Goldman Sachs sold out of Longevity Health Holdings (XAGE) in Q4 2023, closing a stake of 571 shares — an estimated $61.7K sold.

Goldman Sachs first reported a position in XAGE in Q3 2021 and held it in 9 quarters. The position peaked at $4.29M in Q2 2023. 14 funds tracked by Wall St. Rank hold XAGE as of Q4 2023.

  • Goldman Sachs reported no remaining Longevity Health Holdings position as of Q4 2023 after selling out during the quarter.
  • Goldman Sachs sold 571 Longevity Health Holdings shares in Q4 2023, an estimated $61.7K.
  • Goldman Sachs first reported a position in Longevity Health Holdings in Q3 2021 and held it in 9 quarters.
  • Goldman Sachs's Longevity Health Holdings position peaked at $4.29M in Q2 2023.
  • 14 funds tracked by Wall St. Rank held Longevity Health Holdings as of Q4 2023.

Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.